UBS Oconnor LLC Has $413,000 Position in Replimune Group Inc (NASDAQ:REPL)

UBS Oconnor LLC lowered its holdings in shares of Replimune Group Inc (NASDAQ:REPL) by 48.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,200 shares of the company’s stock after selling 26,382 shares during the quarter. UBS Oconnor LLC owned 0.09% of Replimune Group worth $413,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in REPL. BlackRock Inc. raised its position in shares of Replimune Group by 8.2% during the second quarter. BlackRock Inc. now owns 1,015,225 shares of the company’s stock worth $14,883,000 after purchasing an additional 76,540 shares during the period. Victory Capital Management Inc. grew its holdings in shares of Replimune Group by 40.4% during the first quarter. Victory Capital Management Inc. now owns 177,090 shares of the company’s stock worth $2,695,000 after buying an additional 50,950 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Replimune Group by 7.3% during the second quarter. Vanguard Group Inc. now owns 536,564 shares of the company’s stock worth $7,866,000 after buying an additional 36,547 shares in the last quarter. Foresite Capital Management III LLC grew its holdings in shares of Replimune Group by 4.0% during the second quarter. Foresite Capital Management III LLC now owns 779,656 shares of the company’s stock worth $11,430,000 after buying an additional 30,002 shares in the last quarter. Finally, Redmile Group LLC grew its holdings in shares of Replimune Group by 1.1% during the first quarter. Redmile Group LLC now owns 2,212,456 shares of the company’s stock worth $33,674,000 after buying an additional 23,499 shares in the last quarter. 60.74% of the stock is currently owned by institutional investors.

A number of research firms recently issued reports on REPL. Chardan Capital reiterated a “buy” rating and set a $28.00 price objective on shares of Replimune Group in a report on Thursday, August 15th. JPMorgan Chase & Co. upgraded Replimune Group from a “neutral” rating to an “overweight” rating and decreased their price objective for the stock from $27.00 to $26.00 in a report on Friday, July 12th. Roth Capital began coverage on Replimune Group in a report on Wednesday, September 4th. They set a “buy” rating and a $20.00 price objective for the company. HC Wainwright assumed coverage on Replimune Group in a report on Monday, July 8th. They set a “buy” rating and a $26.00 price objective for the company. Finally, ValuEngine upgraded Replimune Group from a “hold” rating to a “buy” rating in a research note on Monday, August 12th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Replimune Group presently has a consensus rating of “Buy” and a consensus target price of $23.33.

Shares of NASDAQ REPL traded up $0.68 during midday trading on Friday, reaching $15.13. The company had a trading volume of 1,906 shares, compared to its average volume of 22,559. The business’s 50-day simple moving average is $11.20 and its 200 day simple moving average is $13.29. The stock has a market cap of $399.63 million, a P/E ratio of -11.35 and a beta of 3.12. Replimune Group Inc has a 1 year low of $8.88 and a 1 year high of $19.99.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.02. Equities analysts expect that Replimune Group Inc will post -1.52 EPS for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Further Reading: Exchange-Traded Funds (ETFs)

Institutional Ownership by Quarter for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.